Immunomodulatory effect of three-day continuous administration of clarithromycin for experimental sepsis due to multidrug-resistant Pseudomonas aeruginosa

Journal of Chemotherapy

Volumn 20, Issue 1, 2008, Pages 63-68

  Baziaka, F ^a   Giamarellos Bourboulis, Evangelos J ^a,b   Raftogiannis, M ^a   Adamis, T ^a   Tziortzioti, V ^a   Sabracos, L ^a   Chrisofos, M ^a   Koutoukas, P ^a   Giamarellou, H ^a   Douzinas, E E ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Clarithromycin; Immunomodulation; Monocytes; Pseudomonas; Sepsis

Indexed keywords

CLARITHROMYCIN; MALONALDEHYDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACUTE PYELONEPHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DRUG MECHANISM; EX VIVO STUDY; IMMUNOMODULATION; MALE; MONOCYTE; MULTIDRUG RESISTANCE; NONHUMAN; ORGAN CULTURE; PROTEIN SECRETION; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS; RABBIT; SEPSIS; SINGLE DRUG DOSE; SURVIVAL RATE;

EID: 41149115725     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.1.63     Document Type: Article

References (12)

1. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2003 34: 1084-93
2. Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2004; 56: 21-8
3. Amsden GW. Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55: 10-21
4. Giamarellos-Bourboulis EJ, Adamis T, Laoutaris G, et al. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004; 48: 93-9
5. Giamarellos-Bourboulis EJ, Baziaka F, Antonopoulou A, et al. Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis by Escherichia coli. Intern J Antimicrob Agents 2005; 25: 168-72
6. Giamarellos-Bourboulis EJ, Adamis T, Sabracos L, et al. Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli. Scand J Infect Dis 2005; 37: 48-54
7. Giamarellos-Bourboulis EJ, Antonopoulou A, Raftogiannis M, et al. Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa. BMC Infect Dis 2006; 6: 31
8. Giamarellos-Bourboulis EJ, Tziortzioti V, Koutoukas P, et al. Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2006; 57: 937-44
9. th International supplement 25: 34-65, 2005
10. Agarwal R, Chase SD. Rapid, fluorometric-liquid chromatographic determination of malondialdehyde in biological samples. J Chromatogr 2002; 775: 121-6
11. Tahan F, Ozcan A, Koc N. Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial. Eur Respir J 2007; 29: 91-97
12. Kikuchi T, Hagiwara K, Honda Y, et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother 2002; 49: 745-55